[A17-41] Ledipasvir/sofosbuvir (hepatitis C) – Benefit assessment according to §35a Social Code Book V
Last updated 15.11.2017
Project no.:
A17-41
Commission:
Commission awarded on 16.08.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Chronic hepatitis C in pretreated and treatment-naive adolescents
Genotype 1 with and without pretreatment: hint of a non-quantifiable added benefit; other genotypes: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A14-44 | Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A20-63 | Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-02-15 A G-BA decision was published.